Mofegiline
Подписчиков: 0, рейтинг: 0
| Clinical data | |
|---|---|
| Other names | MDL-72,974A |
| Routes of administration |
Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 1–3 hours |
| Excretion | Urine |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C11H13F2N |
| Molar mass | 197.229 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Mofegiline (MDL-72,974) is a selective, irreversible inhibitor of monoamine oxidase B (MAO-B) and semicarbazide-sensitive amine oxidase (SSAO) which was under investigation for the treatment of Parkinson's disease and Alzheimer's disease, but was never marketed.
See also
| Food antioxidants |
|
|---|---|
| Fuel antioxidants | |
| Measurements | |
| AChE inhibitor medications | |
|---|---|
| Other medications | |
| Experimental BACE inhibitors | |
| Dopaminergics |
|
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Anticholinergics | |||||||||||
| Others | |||||||||||
| |||||||||||